Sakir bhai
Trying to read between lines here
-
Laurus never gives such vague unusual declarations, on basis of tracking it since last few months they are pretty responsible.
-
Says a global life science company with whom Laurus does not have any prior relation before and wants to start supplies after say 20-30 days in such short period can’t be crams or a new molecule has to be something in which Laurus is a expert n can ramp up soon n fast , so as per rumours in market the needle points out towards paxlovid, as there is huge demand and lots and lots of shortage, so the hurry.
-
Laurus can be a ideal partner due to its huge expertiese in Arv and ability to scale up fast.
-
Also volume n price increasing abnormally in down markets but that can be due to rumours, or institution buying.
Relatively new to pharma so folks who are tracking Laurus since a long time can guide, just trying to read tea leaves here can be horribly wrong just my thoughts, heavily invested so biased no reco take care